Development of a Serum Biomarker Assay That Differentiates Tumor-Associated MUC5AC (NPC-1C ANTIGEN) from Normal MUC5AC

<table>NPC-1C antigen detection in serum during treatment over 3 months. Serum was tested in the NPC-1C sandwich ELISA monthly from colorectal and pancreatic cancer patients over approximately 3 months during which they were being treated for their disease. Trends of increases, decreases, and stable biomarker levels were evaluated in each patient.</table>

BioMed Research International

fig6

Figure 6

Figure 6: Development of a Serum Biomarker Assay That Differentiates Tumor-Associated MUC5AC (NPC-1C ANTIGEN) from Normal MUC5AC 